Product information and disease descriptionProduct descriptionProduct information
Contraindications/Warnings/Precautions/Adverse effects
33 evidence topics · 11 sources
Warnings and precautions
FDA-approved prescribing information for AD109
Not applicable.
Phase 3 trials: most common adverse events and serious adverse events (company statement)
Pooled phase 3 analysis: treatment-emergent adverse events
SynAIRgy: treatment-emergent adverse events in the safety analysis set
Pooled phase 3 analysis: treatment discontinuation due to adverse events by week 26
Pooled phase 3 analysis: overall treatment discontinuation by week 26
Treatment discontinuation due to adverse events and overall treatment discontinuation, SynAIRgy and LunAIRo
SynAIRgy: adverse events leading to treatment discontinuation
“The primary (occurring in ≥7 participants) AEs leading to AD109 discontinuation were insomnia, urinary hesitation, and nausea (Table 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment-emergent adverse event leading to treatment discontinuation | AD109 (n = 325), n (%) | Placebo (n = 319), n (%) |
|---|---|---|
| Insomnia | “16 (4.9)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Urinary hesitation | “8 (2.5)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Nausea | “7 (2.2)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Erectile dysfunction/sexual dysfunction | “5 (1.5)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Dry mouth | “4 (1.2)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Hypertension | “3 (0.9)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Palpitations | “3 (0.9)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
| Urinary retention | “2 (0.6)”View highlighted excerpt for this quote | “0”View highlighted excerpt for this quote |
Insomnia: discontinuation, onset, duration, and severity in the phase 3 trials
Cardiovascular effects: major adverse cardiovascular events and 24-hour ambulatory blood pressure in the phase 3 trials
Cardiovascular effects: heart rate and blood pressure, pooled phase 3 safety analysis set
| Measure | AD109 (n = 653) | Placebo (n = 646) | P value |
|---|---|---|---|
| Heart rate (beats/min), mean change from baseline to week 26, evening before PSG, mean (SD) | “2.0 (11.2)” | “-0.7 (10.0)” | Not reported |
| Heart rate (beats/min), mean change from baseline to week 26, morning after PSG, mean (SD) | “3.4 (9.5)” | “-0.7 (9.4)” | Not reported |
| Systolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.9 (12.0)” | “-1.2 (12.3)” | Not reported |
| Diastolic blood pressure (mm Hg), mean change from baseline to week 26, evening before PSG, mean (SD) | “0.7 (8.4)” | “-1.5 (7.8)” | Not reported |
| Heart rate ≥100 beats/min on study, n (%) | “48 (7.4)” | “28 (4.3)” | “0.021” |
| Systolic blood pressure ≥140 mm Hg on study, n (%) | “175 (26.8)” | “168 (26.0)” | “0.760” |
| Diastolic blood pressure ≥90 mm Hg on study, n (%) | “146 (22.4)” | “131 (20.3)” | “0.368” |
Cardiovascular effects: overnight heart rate over 4 weeks (MARIPOSA)
“Placebo-adjusted mean (95% confidence interval) change from baseline in overnight heart rate was slightly higher in all treatment groups: 7.7 (5.7–9.6), 5.1 (2.9–7.4), and 5.5 (3.3–7.1) beats/min for Ato75, Ad109 2.5/75 mg, and AD109 5/75 mg, respectively (Table 7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiovascular effects: populations excluded from the phase 3 trials and suggested caution
“However, while these changes were small on average, their clinical relevance may vary depending on individual patient characteristics, and careful consideration may be warranted in patients with uncontrolled or resistant hypertension, heart failure, or tachyarrhythmias. Notably, such patients were excluded from the clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adverse events of special interest in the phase 3 trials
“Adverse events of special interest include urinary issues, cardiovascular symptoms, suicidal ideation, daytime sleepiness, motor vehicle accidents, and anticholinergic effects, with a focus on recording patient-reported experiences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Attribution of adverse events to the noradrenergic and antimuscarinic components
“The adverse event profile is consistent with the mechanism of action of AD109. Noradrenergic stimulation may contribute to wake-promoting effects, including insomnia and nausea, while antimuscarinic activity may explain anticholinergic symptoms such as urinary hesitancy and dry mouth.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 1 tolerability (APC-001 and APC-002)
Meta-analysis of atomoxetine combination trials: adverse events, dry mouth, and difficulty with urination
“While the ato group resulted in a significant increase in total AEs (RR = 1.65, 95% CI = 1.28, 2.13, P = 0.0001, I2 = 7%), dry mouth (29.2% vs 9.5%, P = 0.002) and difficulty with urination (10.7% vs 0.8%, P = 0.05).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote